03951nam a22005295i 4500001001800000003000900018005001700027007001500044008004100059020003700100024003500137050001400172072001600186072002300202072001500225245020400240250001800444264007200462300006400534336002600598337002600624338003600650347002400686505140800710520065002118650002502768650003102793650003002824650003002854650002102884650002302905650002502928650003202953650004602985650002303031650002303054700008503077710003403162773002603196776003603222776003603258776003603294856004603330912001403376912001403390999001703404978-981-97-7568-2DE-He21320251030113314.0cr nn 008mamaa241115s2024    si |    s    |||| 0|eng d  a97898197756829978-981-97-7568-27 a10.1007/978-981-97-7568-22doi 4aRM300-666 7aMMG2bicssc 7aMED0710002bisacsh 7aMKG2thema10aSodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failureh[electronic resource] :bMechanisms and Clinical Applications: A Machine-Generated Literature Overview /cedited by Mukesh Nandave.  a1st ed. 2024. 1aSingapore :bSpringer Nature Singapore :bImprint: Springer,c2024.  aXIV, 528 p. 10 illus., 9 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aChapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes  -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor’s effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.  aThe auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage. 0aPharmacology.967844 0aMedicinexResearch.962598 0aBiologyxResearch.965629 0aPharmacovigilance.974275 0aMedicine.963923 0aCardiology.97541014aPharmacology.96784424aBiomedical Research.96563324aDrug Safety and Pharmacovigilance.97427624aClinical Medicine.24aCardiology.9754101 aNandave, Mukesh.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9747242 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978981977567508iPrinted edition:z978981977569908iPrinted edition:z978981977570540uhttps://doi.org/10.1007/978-981-97-7568-2  aZDB-2-SME  aZDB-2-SXM  c64975d64975